Overview
Chemomab is a clinical-stage biotech company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases with large unmet need.
The company’s lead candidate, CM-101, is a first-in-class monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action.
Chemomab is currently promoting in parallel three phase 2 studies, focusing on the rare indications primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).
